Prospective Evaluation of <i>MGMT</i>-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin. The predictive role of MGMT-promoter methylation in this setting is controversial. We sought to pr...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2023-01-01
Reeks:	Current Oncology
Onderwerpen:	neuroendocrine neoplasms chemotherapy biomarkers epigenetic gastroenteropancreatic
Online toegang:	https://www.mdpi.com/1718-7729/30/2/106
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!